Evaxion Biotech A/S

Evaxion Biotech is an AI-immunologyTM platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases.

The biotech company have developed an AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so it can harness its powers through novel immunotherapies. The scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, the company bridge technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients.

AI PLATFORM TECHNOLOGIES We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients. PIONEER is our proprietary AI platform for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI technologies, we seek out and target cancer cells, creating truly personalized therapies, where one size fits one and only one. EDEN is a proprietary AI platform that rapidly identifies those antigens that will trigger a robust protective immune response against almost any bacterial infectious disease. EDEN is fully AI-driven and is designed to identify vaccine candidates faster and at a lower cost than the current state-of-the-art methods. With EDEN we will take a novel approach to vaccine development with the aim of combatting the rising global issue of antibiotic resistance. RAVEN is a proprietary AI-platform that rapidly identifies vaccine candidates against existing, emerging, and mutating viral diseases. We are developing next-generation vaccine candidates that aim to trigger a potent B- and T-cell response simultaneously. Current vaccines against viral disease are challenged by fading efficacy and evasion by mutating viruses. With RAVEN the addition of the T-cell component is designed to secure a more durable and broad protection.